CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Nowakowski, Grzegorz S
Chiappella, Annalisa
Gascoyne, Randy D
Scott, David W
Zhang, Qingyuan
Jurczak, Wojciech
Özcan, Muhit
Hong, Xiaonan
Zhu, Jun
Jin, Jie
Belada, David
Bergua, Juan Miguel
Piazza, Francesco
Mócikova, Heidi
Molinari, Anna Lia
Yoon, Dok Hyun
Cavallo, Federica
Tani, Monica
Yamamoto, Kazuhito
Izutsu, Koji
Kato, Koji
Czuczman, Myron
Hersey, Sarah
Kilcoyne, Adrian
Russo, Jacqueline
Hudak, Krista
Zhang, Jingshan
Wade, Steve
Witzig, Thomas E
Vitolo, Umberto

January 2021

Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) histo...

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

K. Lisenko
G. Dingeldein
M. Cremer
M. Kriegsmann
A. D. Ho
M. Rieger
M. Witzens-Harig

May 2017

Abstract Background The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristin...

R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)

Lamy, Thierry
Damaj, Gandhi
Soubeyran, Pierre
Gyan, Emmanuel
Cartron, Guillaume
Bouabdallah, Krimo
Gressin, Rémy
Cornillon, Jérôme
Banos, Anne
Le Du, Katell
Benchalal, Mohamed
Moles, Marie-Pierre
Le Gouill, Steven
Fleury, Joel
Godmer, Pascal
Maisonneuve, Hervé
Deconinck, Eric
Houot, Roch
Laribi, Kamel
Marolleau, Jean Pierre
Tournilhac, Olivier
Branger, Bernard
Devillers, Anne
Vuilliez, Philippe
Fest, Thierry
Colombat, Philippe
Costes, Valérie
Szablewski, Vanessa
Béné, Marie C.
Delwail, Vincent

January 2018

International audienceThe benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse l...

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M.
Kuhnt E.
Trümper L.
Osterborg A.
Trneny M.
Shepherd L.
Gill D.S.
Walewski J.
Pettengell R.
Jaeger U.
Zinzani P.L.
Shpilberg O.
Kvaloy S.
de Nully Brown P.
Stahel R.
Milpied N.
López-Guillermo A.
Poeschel V.
Grass S.
Loeffler M.
Murawski N.
MabThera International Trial (MInT) Group

January 2011

BACKGROUND: The MInT study was the first to show improved 3-year outcomes with the addition of ritu...

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Pfreundschuh, M
Kuhnt, E
Trümper, L
Osterborg, A
Trneny, M
Shepherd, L
Gill, D S
Walewski, J
Pettengell, R
Jaeger, U
Zinzani, P L
Shpilberg, O
Kvaloy, S
de Nully Brown, P
Stahel, R
Milpied, N
López-Guillermo, A
Poeschel, V
Grass, S
Loeffler, M
Murawski, N

January 2011

BACKGROUND: The MInT study was the first to show improved 3-year outcomes with the addition of ritu...

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Poeschel V.
Held G.
Ziepert M.
Witzens-Harig M.
Holte H.
Thurner L.
Borchmann P.
Viardot A.
Soekler M.
Keller U.
Schmidt C.
Truemper L.
Mahlberg R.
Marks R.
Hoeffkes H. -G.
Metzner B.
Dierlamm J.
Frickhofen N.
Haenel M.
Neubauer A.
Kneba M.
Merli F.
Tucci A.
de Nully Brown P.
Federico M.
Lengfelder E.
di Rocco A.
Trappe R.
Rosenwald A.
Berdel C.
Maisenhoelder M.
Shpilberg O.
Amam J.
Christofyllakis K.
Hartmann F.
Murawski N.
Stilgenbauer S.
Nickelsen M.
Wulf G.
Glass B.
Schmitz N.
Altmann B.
Loeffler M.
Pfreundschuh M.

January 2019

Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

Récher, C.
Coiffier, B.
Haioun, C.
Molina, T.J.
Fermé, C.
Casasnovas, O.
Thiéblemont, C.
Bosly, A.
Laurent, G.
Morschhauser, F.
Ghesquières, H.
Jardin, F.
Bologna, S.
Fruchart, C.
Corront, B.
Gabarre, J.
Bonnet, C.
Janvier, M.
Canioni, D.
Jais, J.P.
Salles, G.
Tilly, H.

January 2011

BACKGROUND: The outcome of diffuse large B-cell lymphoma has been substantially improved by the addi...

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

January 2020

13The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still hi...

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study

David Belada
Lukáš Smolej
Monika Hrudková
Pavla Štěpánková
Alice Sýkorová
Pavel Žák
Jiří Bukač
Jaroslav Malý

January 2007

CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma...

CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma - a meta-analysis of randomized controlled trials

Vidal, Liat
Shpilberg, Ofer
Gurion, Ronit
Monsef, Ina
Raanani, Pia
Ram, Ron
Gafter-Gvili, Anat

January 2016

Background. R-CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma. ...

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin\u2019s lymphoma: evidence from a multicenter, retrospective study

Mondello, Patrizia
Steiner, Normann
Willenbacher, Wolfgang
Wasle, Ines
Zaja, Francesco
Zambello, Renato
Visentin, Andrea
Mauro, Endri
Ferrero, Simone
Ghione, Paola
Pitini, Vincenzo
Cuzzocrea, Salvatore
Mian, Michael

January 2016

The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still high...

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

January 2020

26BACKGROUND: The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-a...

Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas

Cortelazzo S.
Tarella C.
Gianni A. M.
Ladetto M.
Barbui A. M.
Rossi A.
Gritti G.
Corradini P.
Di Nicola M.
Patti C.
Mule A.
Zanni M.
Zoli V.
Billio A.
Piccin A.
Negri G.
Castellino C.
Di Raimondo F.
Ferreri A. J. M.
Benedetti F.
La Nasa G.
Gini G.
Trentin L.
Frezzato M.
Flenghi L.
Falorio S.
Chilosi M.
Bruna R.
Tabanelli V.
Pileri S.
Masciulli A.
Delaini F.
Boschini C.
Rambaldi A.

January 2016

Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as fi...

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma

T. D. Lutskaya
A. K. Golenkov
T. A. Mitina
I. V. Buravtsova
G. A. Dudina
L. L. Vysotskaya
E. V. Trifonova
E. V. Kataeva
O. V. Moskalets
V. V. Yazdovskiy

July 2014

<p>This study aimed to evaluate treatment results in patients with diffuse large cell lymphoma (DBL ...

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas

Cortelazzo, S.
Tarella, C.
Gianni, A. M.
Ladetto, M.
Barbui, A. M.
Rossi, A.
Gritti, G.
Corradini, P.
Di Nicola, M.
Patti, C.
Mule, A.
Zanni, M.
Zoli, V.
Billio, A.
Piccin, A.
Negri, G.
Castellino, C.
Di Raimondo, F.
Ferreri, A. J. M.
Benedetti, F.
Gini, G.
Trentin, L.
Frezzato, M.
Flenghi, L.
Falorio, S.
Chilosi, M.
Bruna, R.
Tabanelli, V.
Pileri, S.
Masciulli, A.
Delaini, F.
Boschini, C.
Rambaldi, A.
LA NASA, GIORGIO

January 2016

Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as fi...

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Nowakowski, Grzegorz S
Chiappella, Annalisa
Gascoyne, Randy D
Scott, David W
Zhang, Qingyuan
Jurczak, Wojciech
Özcan, Muhit
Hong, Xiaonan
Zhu, Jun
Jin, Jie
Belada, David
Bergua, Juan Miguel
Piazza, Francesco
Mócikova, Heidi
Molinari, Anna Lia
Yoon, Dok Hyun
Cavallo, Federica
Tani, Monica
Yamamoto, Kazuhito
Izutsu, Koji
Kato, Koji
Czuczman, Myron
Hersey, Sarah
Kilcoyne, Adrian
Russo, Jacqueline
Hudak, Krista
Zhang, Jingshan
Wade, Steve
Witzig, Thomas E
Vitolo, Umberto

January 2021

Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) histo...

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

K. Lisenko
G. Dingeldein
M. Cremer
M. Kriegsmann
A. D. Ho
M. Rieger
M. Witzens-Harig

May 2017

Abstract Background The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristin...

R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)

Lamy, Thierry
Damaj, Gandhi
Soubeyran, Pierre
Gyan, Emmanuel
Cartron, Guillaume
Bouabdallah, Krimo
Gressin, Rémy
Cornillon, Jérôme
Banos, Anne
Le Du, Katell
Benchalal, Mohamed
Moles, Marie-Pierre
Le Gouill, Steven
Fleury, Joel
Godmer, Pascal
Maisonneuve, Hervé
Deconinck, Eric
Houot, Roch
Laribi, Kamel
Marolleau, Jean Pierre
Tournilhac, Olivier
Branger, Bernard
Devillers, Anne
Vuilliez, Philippe
Fest, Thierry
Colombat, Philippe
Costes, Valérie
Szablewski, Vanessa
Béné, Marie C.
Delwail, Vincent

January 2018

International audienceThe benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse l...

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M.
Kuhnt E.
Trümper L.
Osterborg A.
Trneny M.
Shepherd L.
Gill D.S.
Walewski J.
Pettengell R.
Jaeger U.
Zinzani P.L.
Shpilberg O.
Kvaloy S.
de Nully Brown P.
Stahel R.
Milpied N.
López-Guillermo A.
Poeschel V.
Grass S.
Loeffler M.
Murawski N.
MabThera International Trial (MInT) Group

January 2011

BACKGROUND: The MInT study was the first to show improved 3-year outcomes with the addition of ritu...

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Pfreundschuh, M
Kuhnt, E
Trümper, L
Osterborg, A
Trneny, M
Shepherd, L
Gill, D S
Walewski, J
Pettengell, R
Jaeger, U
Zinzani, P L
Shpilberg, O
Kvaloy, S
de Nully Brown, P
Stahel, R
Milpied, N
López-Guillermo, A
Poeschel, V
Grass, S
Loeffler, M
Murawski, N

January 2011

BACKGROUND: The MInT study was the first to show improved 3-year outcomes with the addition of ritu...

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Poeschel V.
Held G.
Ziepert M.
Witzens-Harig M.
Holte H.
Thurner L.
Borchmann P.
Viardot A.
Soekler M.
Keller U.
Schmidt C.
Truemper L.
Mahlberg R.
Marks R.
Hoeffkes H. -G.
Metzner B.
Dierlamm J.
Frickhofen N.
Haenel M.
Neubauer A.
Kneba M.
Merli F.
Tucci A.
de Nully Brown P.
Federico M.
Lengfelder E.
di Rocco A.
Trappe R.
Rosenwald A.
Berdel C.
Maisenhoelder M.
Shpilberg O.
Amam J.
Christofyllakis K.
Hartmann F.
Murawski N.
Stilgenbauer S.
Nickelsen M.
Wulf G.
Glass B.
Schmitz N.
Altmann B.
Loeffler M.
Pfreundschuh M.

January 2019

Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

Récher, C.
Coiffier, B.
Haioun, C.
Molina, T.J.
Fermé, C.
Casasnovas, O.
Thiéblemont, C.
Bosly, A.
Laurent, G.
Morschhauser, F.
Ghesquières, H.
Jardin, F.
Bologna, S.
Fruchart, C.
Corront, B.
Gabarre, J.
Bonnet, C.
Janvier, M.
Canioni, D.
Jais, J.P.
Salles, G.
Tilly, H.

January 2011

BACKGROUND: The outcome of diffuse large B-cell lymphoma has been substantially improved by the addi...

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

January 2020

13The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still hi...

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study

David Belada
Lukáš Smolej
Monika Hrudková
Pavla Štěpánková
Alice Sýkorová
Pavel Žák
Jiří Bukač
Jaroslav Malý

January 2007

CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma...

CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma - a meta-analysis of randomized controlled trials

Vidal, Liat
Shpilberg, Ofer
Gurion, Ronit
Monsef, Ina
Raanani, Pia
Ram, Ron
Gafter-Gvili, Anat

January 2016

Background. R-CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma. ...

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin\u2019s lymphoma: evidence from a multicenter, retrospective study

Mondello, Patrizia
Steiner, Normann
Willenbacher, Wolfgang
Wasle, Ines
Zaja, Francesco
Zambello, Renato
Visentin, Andrea
Mauro, Endri
Ferrero, Simone
Ghione, Paola
Pitini, Vincenzo
Cuzzocrea, Salvatore
Mian, Michael

January 2016

The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still high...

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

January 2020

26BACKGROUND: The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-a...

Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas

Cortelazzo S.
Tarella C.
Gianni A. M.
Ladetto M.
Barbui A. M.
Rossi A.
Gritti G.
Corradini P.
Di Nicola M.
Patti C.
Mule A.
Zanni M.
Zoli V.
Billio A.
Piccin A.
Negri G.
Castellino C.
Di Raimondo F.
Ferreri A. J. M.
Benedetti F.
La Nasa G.
Gini G.
Trentin L.
Frezzato M.
Flenghi L.
Falorio S.
Chilosi M.
Bruna R.
Tabanelli V.
Pileri S.
Masciulli A.
Delaini F.
Boschini C.
Rambaldi A.

January 2016

Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as fi...

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma

T. D. Lutskaya
A. K. Golenkov
T. A. Mitina
I. V. Buravtsova
G. A. Dudina
L. L. Vysotskaya
E. V. Trifonova
E. V. Kataeva
O. V. Moskalets
V. V. Yazdovskiy

July 2014

<p>This study aimed to evaluate treatment results in patients with diffuse large cell lymphoma (DBL ...

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas

Cortelazzo, S.
Tarella, C.
Gianni, A. M.
Ladetto, M.
Barbui, A. M.
Rossi, A.
Gritti, G.
Corradini, P.
Di Nicola, M.
Patti, C.
Mule, A.
Zanni, M.
Zoli, V.
Billio, A.
Piccin, A.
Negri, G.
Castellino, C.
Di Raimondo, F.
Ferreri, A. J. M.
Benedetti, F.
Gini, G.
Trentin, L.
Frezzato, M.
Flenghi, L.
Falorio, S.
Chilosi, M.
Bruna, R.
Tabanelli, V.
Pileri, S.
Masciulli, A.
Delaini, F.
Boschini, C.
Rambaldi, A.
LA NASA, GIORGIO

January 2016

Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as fi...

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Nowakowski, Grzegorz S
Chiappella, Annalisa
Gascoyne, Randy D
Scott, David W
Zhang, Qingyuan
Jurczak, Wojciech
Özcan, Muhit
Hong, Xiaonan
Zhu, Jun
Jin, Jie
Belada, David
Bergua, Juan Miguel
Piazza, Francesco
Mócikova, Heidi
Molinari, Anna Lia
Yoon, Dok Hyun
Cavallo, Federica
Tani, Monica
Yamamoto, Kazuhito
Izutsu, Koji
Kato, Koji
Czuczman, Myron
Hersey, Sarah
Kilcoyne, Adrian
Russo, Jacqueline
Hudak, Krista
Zhang, Jingshan
Wade, Steve
Witzig, Thomas E
Vitolo, Umberto

January 2021

Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) histo...

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

K. Lisenko
G. Dingeldein
M. Cremer
M. Kriegsmann
A. D. Ho
M. Rieger
M. Witzens-Harig

May 2017

Abstract Background The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristin...

R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)

Lamy, Thierry
Damaj, Gandhi
Soubeyran, Pierre
Gyan, Emmanuel
Cartron, Guillaume
Bouabdallah, Krimo
Gressin, Rémy
Cornillon, Jérôme
Banos, Anne
Le Du, Katell
Benchalal, Mohamed
Moles, Marie-Pierre
Le Gouill, Steven
Fleury, Joel
Godmer, Pascal
Maisonneuve, Hervé
Deconinck, Eric
Houot, Roch
Laribi, Kamel
Marolleau, Jean Pierre
Tournilhac, Olivier
Branger, Bernard
Devillers, Anne
Vuilliez, Philippe
Fest, Thierry
Colombat, Philippe
Costes, Valérie
Szablewski, Vanessa
Béné, Marie C.
Delwail, Vincent

January 2018

International audienceThe benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse l...

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Abstract

Extracted data

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Abstract

Extracted data

Related items

Related items